Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603382 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 599
- Enrollment target
NCT00603382: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00603382 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 599 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (350% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00603382, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 599 participants
- Enrollment target
Study Summary
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
Primary Outcome
Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Pre-dose and pre-rescue bronchodilator (albuterol/salbutamol) trough FEV1(the measurement of FEV1 performed at the end of the dosing interval) was measured electronically by spirometry in the evening at the Baseline through Week 8 clinic visits. Trough FEV1 is the FEV1 measured approximately 24 hours after the last adm
Interventions
- DRUG Placebo
- DRUG GW685698X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2007-12-01 |
| Est. Completion | 2008-10-02 |
| Phase | Phase 2 |
What the finished NCT00603382 record still lists
NCT00603382 is an interventional study that assigns participants to a tested intervention. The registered 599 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (350% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00603382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00603382 about?
NCT00603382 is a clinical study titled "A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.". This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
What is the current status of trial NCT00603382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 599 participants. The study started on 2007-12-01. Estimated completion is 2008-10-02.
What interventions are being tested in trial NCT00603382?
The interventions under investigation include: Placebo (DRUG), GW685698X (DRUG).
Who is sponsoring clinical trial NCT00603382?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00603382's enrollment target sits among peer trials
599 56th of 2000 higher than 1,945 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI